Rule 497(d)
FT 422
Biotechnology Select Portfolio, Series 3
Digital Convergence Select Portfolio, Series 2
Fiber Optics Select Portfolio, Series 2
Genomics & Proteomics Select Portfolio, Series 2
Pharmaceutical Select Portfolio, Series 3
Storage & Networking Select Portfolio Series
Technology Select Portfolio, Series 3
Biotechnology Portfolio, Series 3
Digital Convergence Portfolio, Series 2
Fiber Optics Portfolio, Series 2
Genomics & Proteomics Portfolio, Series 2
Pharmaceutical Portfolio, Series 9
Storage & Networking Portfolio Series
Technology Portfolio, Series 12
Supplement to the Prospectus dated March 22, 2000
Notwithstanding anything to the contrary in the Prospectus, Unit holders who
acquire Units of Fiber Optics Portfolio, Series 2, Genomics & Proteomics Select
Portfolio, Series 2, Genomics & Proteomics Portfolio, Series 2 or Storage &
Networking Portfolio Series which, as a result of a reduction in the aggregate
underlying value of the Securities, are not subject to an initial sales charge
will be subject to the maximum remaining deferred sales charge (initially $.225
per Unit in the case of Genomics & Proteomics Select Portfolio, Series 2 or
$.35 per Unit for Fiber Optics Portfolio, Series 2, Genomics & Proteomics
Portfolio, Series 2 or Storage & Networking Portfolio Series). In such case the
maximum sales charge may exceed 3.25% of the Public Offering Price per Unit for
Genomics & Proteomics Select Portfolio, Series 2 or 4.5% of the Public Offering
Price per Unit for Fiber Optics Portfolio, Series 2, Genomics & Proteomics
Portfolio, Series 2 or Storage & Networking Portfolio Series, but in no event
will the maximum sales charge exceed 3.75% of the Public Offering Price per Unit
for Genomics & Proteomics Select Portfolio, Series 2, 5.00% of the Public
Offering Price per Unit for Fiber Optics Portfolio, Series 2 or Storage &
Networking Portfolio Series or 5.50% of the Public Offering Price per Unit for
Genomics & Proteomics Portfolio, Series 2.
April 11, 2000